What ATLAS Biolabs does

ATLAS Biolabs, operated by Atlas Life Sciences GmbH and headquartered in Berlin, is a molecular diagnostics infrastructure company that has operated for 20+ years in sequencing, array-based analysis, and bioinformatics. The company positions itself as the operational layer beneath modern molecular diagnostics, offering an integrated platform — Atlas OS — that combines digital order management, automated laboratory routing, wet-lab processing, and bioinformatics pipelines into a single end-to-end system. Service offerings include Next-Generation Sequencing (whole genome, whole exome, targeted panels, amplicons), Molecular Karyotyping (CytoScan-based CNV/LOH detection), Epigenomics & Methylation, Pharmacogenomics, and Proteomics & Multi-Omics.

The company serves enterprise customers across three primary verticals: global pharmaceutical companies (including Bayer, Boehringer Ingelheim, Novartis, and Sanofi), academic and university medicine (Charité Berlin, Max Planck Society), and clinical diagnostics laboratories. Its go-to-market combines a self-serve digital platform (Atlas Portal) for direct sample submission and order creation with a partner laboratory network (Life & Brain, MDI Limbach Berlin) coordinated by Atlas Operator, and is supported by a technology ecosystem relationship with Thermo Fisher Scientific. The company claims 2,000+ customers served and 100,000+ samples processed cumulatively.

Atlas generates revenue through service-based laboratory fees for molecular analysis work, with quote-based enterprise pricing rather than publicly disclosed rate cards. The business model is a hybrid of direct enterprise lab services and a platform-mediated, routed distribution model that leverages partner lab capacity. Headcount is reported at 11–50 employees, and the company is privately held with no disclosed venture capital, private equity, or parent company ownership in the source data. The CEO is Paul Froutan. No funding rounds, acquisitions, regulatory actions, patents, or certifications were disclosed in the available material.

Name

ATLAS Biolabs

Legal name

Atlas Life Sciences GmbH

Website

https://atlas-biolabs.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

ATLAS Biolabs is a Berlin-based molecular diagnostics infrastructure company offering an integrated platform (Atlas OS) that combines digital order management, automated laboratory routing, wet-lab processing, and bioinformatics to serve global pharmaceutical, academic research, and clinical diagnostics customers with genomic and multi-omics analysis services.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

akta.pro secondary industries

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

Keywords

• Molecular diagnostics services
• Next-generation sequencing
• Bioinformatics analysis
• Pharmacogenomics testing
• Genome analysis

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Molecular Diagnostics Laboratory Services: Atlas provides molecular analysis services including NGS, molecular karyotyping, epigenomics, pharmacogenomics, and proteomics. Revenue is generated through laboratory service fees charged to pharma, research, and clinical diagnostic customers. The platform routes orders to internal or partner laboratories under standardized operational protocols.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

ATLAS Biolabs operates a molecular diagnostics infrastructure combining wet-lab processing, bioinformatics, and digital workflow software. The company provides next-generation sequencing, molecular karyotyping, epigenomics, pharmacogenomics, and proteomics services routed through the Atlas OS platform, which integrates digital order management, automated laboratory assignment, sequencing/array processing, and structured report delivery. Services are delivered to enterprise customers in pharmaceutical, clinical diagnostics, and academic research sectors under standardized operational protocols.

Product overview

ATLAS Biolabs offers a unified platform-plus-modules architecture built around Atlas OS, an operational system for molecular diagnostics. The platform integrates multiple components: Atlas Portal (customer-facing interface for orders and results), Atlas Operator (automated routing), Atlas Lab (wet lab processing), and Atlas Bioinformatics (analysis and interpretation). These modules work together as an end-to-end operational system spanning sample intake, laboratory assignment, execution, review, and delivery. The service portfolio includes Next-Generation Sequencing (whole genome, exome, panels, amplicons), Molecular Karyotyping (CytoScan-based CNV/LOH detection), Epigenomics & Methylation profiling, Pharmacogenomics for medication optimization, and Proteomics & Multi-Omics. Atlas Protocol serves as a discovery platform for exploring diagnostic protocols.

Differentiator

Problem solved

Functional benefit

Products and services

• Atlas OS Operational system layer beneath molecular diagnostics that integrates software, laboratory workflows, and structured data delivery into a single layer for intake, routing, analysis, and delivery across laboratories, clinics, and care networks.
• Atlas Portal Customer-facing digital platform for sample intake, order creation, digital consent capture, sample metadata management, service selection, and structured result delivery. Reports are tracked, versioned, and available alongside the original order record.
• Atlas Protocol Discovery platform for exploring and understanding Atlas Biolabs' diagnostic protocols and services.
• Next-Generation Sequencing (NGS) Whole genome, whole exome, targeted panels, and amplicon sequencing services run under standardized operational standards across established and emerging platforms, for pharma, research, and clinical diagnostics customers.
• Molecular Karyotyping CytoScan-based genome-wide copy number variation (CNV) and loss of heterozygosity (LOH) detection for molecular cytogenetic analysis.
• Epigenomics & Methylation Genome-wide and targeted methylation profiling services for epigenetic analysis.
• Pharmacogenomics (PGx) Preemptive pharmacogenomic profiling for medication optimization, enabling personalized drug selection based on genetic makeup.
• Proteomics & Multi-Omics Protein-level analysis integrated with genomic data for comprehensive multi-omics profiling.
• Bioinformatics Services Custom pipelines, variant calling, quality control, and interpretation services for molecular diagnostics results, preparing them for structured and auditable delivery.

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Thermo Fisher ScientificcoreTechnology or IntegrationThermo Fisher Scientific is featured in Atlas's ecosystem as a selected relationship in diagnostics infrastructure. The partnership provides Atlas access to established laboratory technology platforms for molecular diagnostics operations.
• Life & BraincoreTechnology or IntegrationLife & Brain is listed as a partner laboratory in Atlas's diagnostics infrastructure ecosystem. The partnership enables routing of orders to Life & Brain facilities based on capacity and capability requirements under standardized Atlas operational rules.
• MDI Limbach BerlincoreChannel Partner/ Reseller/ DistributorMDI Limbach Berlin is featured in Atlas's ecosystem as a selected relationship in diagnostics infrastructure. As a partner laboratory, orders are routed to MDI Limbach based on optimal laboratory assignment criteria including capacity and turnaround time.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Macrogen: Korea-based global genomics services company providing NGS, Sanger sequencing, microarray, and bioinformatics to pharma, clinical, and research customers. Comparable across service mix, customer segments, and international delivery.
• CeGaT: Tübingen-based genomics and multi-omics services provider offering NGS, panels, and bioinformatics for pharma, research, and clinical customers. Closest direct peer to Atlas given German base, similar service portfolio, and overlapping pharma and academic customer base.
• Novogene: Leading global NGS services provider with whole genome, exome, transcriptomics, and epigenomics offerings for pharma and academic customers. Directly comparable on service catalog, customer segments, and global delivery model.

Broad incumbents

• QIAGEN: Global leader in sample preparation, molecular diagnostics assays, and bioinformatics (including the N-of-One acquired assets). Comparable at the bioinformatics and molecular diagnostics intersection, though QIAGEN is a much larger broad incumbent with its own assay portfolio.
• BGI Genomics: One of the largest global genomics services organizations, with broad NGS, reproductive health, and clinical diagnostics offerings. Comparable in services but vastly larger scale and geographic footprint.
• NeoGenomics: US-based clinical oncology-focused molecular diagnostics and contract research services company. Comparable in clinical molecular diagnostics services and pharma CRO offerings, but at much larger scale and oncology-centric scope.
• Thermo Fisher Scientific (Clinical NGS services): Atlas's named ecosystem partner and a global leader in sequencing instruments, NGS reagents, and clinical NGS services. Comparable at the molecular diagnostics infrastructure layer, though Thermo Fisher is a broad incumbent with much greater scale and instrument ownership.
• Eurofins Genomics: Global genomics services arm of Eurofins Scientific, offering sequencing, genotyping, oligonucleotides, and bioinformatics at much larger scale. Comparable offering but as a much broader incumbent across many geographies and assay types.

Emerging players

• MedGenome: India- and US-based genomics and molecular diagnostics services company focused on genetic testing, NGS panels, and pharmacogenomics. Comparable in molecular diagnostics services for clinical and research customers, though at a different scale and geographic focus.
• Strand Life Sciences: India-based company combining clinical genomics diagnostics, bioinformatics software, and pharma biomarker services. Comparable across multi-omics analytics and pharma services, though with a different geographic and customer mix.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/atlas-biolabs-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ATLAS Biolabs